List of Excipients in Branded Drug TENCON

Generic Drugs Containing TENCON

Company	Ingredient	NDC	Excipient
El Dorado Distributors LLC	butalbital and acetaminophen	11584-0030	CELLULOSE, MICROCRYSTALLINE
El Dorado Distributors LLC	butalbital and acetaminophen	11584-0030	CROSCARMELLOSE SODIUM
El Dorado Distributors LLC	butalbital and acetaminophen	11584-0030	CROSPOVIDONE

What are the Most Frequently-Used Excipients in TENCON?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE

# TENCON Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Patent Risk

Last updated: August 9, 2026

TENCON is an immediate-release oral combination of butalbital, acetaminophen, and caffeine used for tension or muscle-contraction headaches. The product’s commercial opportunity is primarily generic and formulation-driven rather than patent-driven. The strongest strategies are cost-efficient tablet manufacture, excipient differentiation for tolerability and supply security, dosage-form improvements, and private-label distribution. Core composition-of-matter patent protection is not the principal barrier because all three active ingredients are long-established generic substances.

What is TENCON and what formulation is marketed?

TENCON is labeled as a prescription tablet containing:

Active ingredient	Typical labeled amount per tablet	Functional role
Butalbital	50 mg	Barbiturate central nervous system depressant
Acetaminophen	325 mg	Analgesic
Caffeine	40 mg	Analgesic adjunct

The product is an immediate-release, solid oral dosage form. Its commercial reference is the broader butalbital-acetaminophen-caffeine product class, which includes Fioricet and multiple generic equivalents. TENCON is subject to prescription controls because of butalbital and carries warnings relating to dependence, withdrawal, sedation, medication-overuse headache, and acetaminophen-associated liver injury.[1]

The tablet format limits the value of complex delivery technology. A differentiated excipient platform must improve manufacturability, patient acceptability, stability, or supply economics without creating avoidable bioequivalence and regulatory burdens.

What excipients are used in TENCON tablets?

Public product labeling identifies conventional tablet excipients, including diluents, binders, disintegrants, lubricants, glidants, and coloring agents. The listed inactive ingredients for marketed butalbital-acetaminophen-caffeine tablets can include microcrystalline cellulose, starch, croscarmellose sodium, povidone, colloidal silicon dioxide, magnesium stearate, talc, sodium lauryl sulfate, and permitted colorants.[2]

The exact excipient list can vary by manufacturer, strength, imprint, and manufacturing site. A generic applicant must match the reference product’s active ingredients, dosage form, route, strength, and performance characteristics under the applicable ANDA pathway. Inactive ingredients do not need to be identical in every case, but differences must comply with FDA inactive-ingredient requirements and must not affect safety, performance, or bioequivalence.[3]

What functions do the principal excipients perform?

Excipient category	Common examples	Commercial purpose
Diluent	Microcrystalline cellulose, starch	Provides tablet mass and compressibility
Binder	Povidone, pregelatinized starch	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, starch	Promotes rapid tablet breakup
Lubricant	Magnesium stearate	Reduces adhesion and ejection force
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Surfactant or wetting agent	Sodium lauryl sulfate	Supports wetting and process uniformity
Colorant	FD&C or D&C dyes	Product identification and differentiation

The principal formulation risks are not unusual for an immediate-release tablet. Excessive lubricant levels can slow dissolution. High binder levels can delay disintegration. Acetaminophen can create blend-uniformity and compression challenges because it may have poor flow and compressibility depending on the particle grade. Butalbital and caffeine are present at lower quantities and require control of content uniformity.

What excipient strategy best fits TENCON?

The highest-value strategy is a robust, low-complexity direct-compression or dry-granulation formulation that preserves rapid dissolution and minimizes dependence on constrained excipient suppliers.

Direct-compression strategy

A direct-compression platform can use:

• Co-processed microcrystalline cellulose and silicified microcrystalline cellulose for flow and compactibility.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Low-level magnesium stearate with controlled blending time.
• Colloidal silicon dioxide for flow improvement.
• A low-dust, directly compressible acetaminophen grade.

This approach can reduce water exposure, shorten processing time, and lower equipment requirements. It is commercially attractive for contract manufacturers and regional generic suppliers. The principal technical risk is segregation because the formula contains three active ingredients with different particle sizes, densities, and concentrations.

Dry-granulation strategy

Roller compaction or slugging provides a stronger option where acetaminophen flow or content uniformity is inadequate. Dry granulation avoids aqueous processing and can improve:

• Blend uniformity
• Tablet weight control
• Compression performance
• Manufacturing resilience across sites

The tradeoff is additional process development, possible fines generation, and the need to demonstrate that granulation does not alter dissolution or active-ingredient distribution.

Wet-granulation strategy

Wet granulation can improve uniformity and tablet strength but is less attractive as a default platform. It adds drying cost and introduces potential stability and color-variation issues. It is most defensible when the selected active-material grades cannot meet flow or compression targets through direct compression or dry granulation.

What formulation patents could protect a TENCON product?

A conventional TENCON tablet is unlikely to support broad, high-value formulation patent protection solely because of a standard excipient mixture. A patent strategy would need a defined technical result, such as:

• A measurable reduction in tablet disintegration time.
• Improved dissolution under a discriminatory method.
• Enhanced content uniformity at commercial scale.
• Reduced friability at lower compression force.
• Improved chemical stability under accelerated storage.
• Reduced bitterness or improved patient acceptability.
• A novel abuse-deterrent or tamper-resistant system.
• A distinct modified-release profile.

A claim that merely substitutes one common diluent or disintegrant for another would face substantial obviousness risk. The strongest formulation claim would connect a specific excipient ratio or processing condition to an unexpected performance result.

What excipient combinations have the best patent potential?

Potentially protectable concepts include:

1. A low-moisture, direct-compression composition using a defined acetaminophen particle-size distribution and a specified co-processed filler.
2. A rapid-disintegration tablet using a particular disintegrant combination that maintains dissolution after prolonged storage.
3. A low-sodium or sodium-lauryl-sulfate-free formulation with equivalent wetting and dissolution performance.
4. A formulation that limits segregation of butalbital, acetaminophen, and caffeine during high-speed tableting.
5. A film-coated tablet with improved light and humidity protection without delaying release.

The applicant would need comparative data against the reference product and conventional formulations. Patent value would depend on whether competitors could design around the excipient ratios without losing the claimed performance.

When does TENCON lose exclusivity and what is the Orange Book status?

TENCON’s commercial exclusivity position is primarily determined by the age of the active ingredients and the regulatory status of the specific listed product. Butalbital, acetaminophen, and caffeine have long generic histories. The relevant competitive question is therefore whether the particular TENCON product has an active NDA, unexpired regulatory exclusivity, or listed patents.

For an established immediate-release combination of these ingredients:

• New chemical entity exclusivity is not relevant.
• Orphan-drug exclusivity is not relevant.
• Biosimilar exclusivity is not relevant.
• Pediatric exclusivity is not inherent to the product class.
• Any patent protection would more likely involve a specific formulation, method of use, packaging system, or manufacturing process.
• Generic applicants would normally evaluate the product under the ANDA pathway if a reference listed drug and applicable FDA requirements are satisfied.

Orange Book status must be assessed against the current FDA publication and the exact product sponsor. A product-level review should distinguish TENCON from Fioricet and other butalbital combinations because Orange Book listings, approval holders, and patent certifications can differ by reference product.[4]

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV challenge is commercially relevant only if the reference product has an unexpired Orange Book patent. A generic applicant certifying that a listed patent is invalid, unenforceable, or will not be infringed can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[5]

For TENCON, the practical entry risks are more likely to involve:

• FDA review of active-ingredient equivalence.
• Dissolution failure caused by excipient substitutions.
• Content-uniformity problems.
• Controlled-substance manufacturing and distribution requirements.
• Labeling differences involving dependence and acetaminophen warnings.
• Supply-chain controls for butalbital.
• Commercially weak pricing because many suppliers can enter the category.

A conventional ANDA could enter quickly if no blocking patent or exclusivity remains and the applicant demonstrates bioequivalence. A formulation with a novel delivery profile, abuse-deterrent feature, or new clinical positioning could require a 505(b)(2) application instead of an ANDA.[6]

What FDA regulatory requirements affect TENCON excipient development?

The development program must address both pharmaceutical equivalence and product-specific safety. Key regulatory requirements include:

Area	TENCON-specific implication
Dosage form	Immediate-release tablet must maintain comparable release characteristics
Bioequivalence	Pharmacokinetic comparison is generally required for the combination product
Inactive ingredients	New or unusual excipients may require toxicology justification
Dissolution	Method must discriminate between acceptable and unacceptable formulations
Content uniformity	Important because butalbital and caffeine are present at lower amounts
Stability	Acetaminophen degradation, moisture, light, and color changes require monitoring
Controlled substance	Butalbital requires applicable DEA controls and recordkeeping
Labeling	Dependence, sedation, medication-overuse headache, and liver-risk warnings apply
Manufacturing	Current good manufacturing practice requirements apply to all commercial sites

Excipient changes should be managed through a formal risk assessment linking material attributes to critical quality attributes. The most important attributes are tablet hardness, friability, disintegration, dissolution, assay, degradation products, and content uniformity.

What commercial opportunities exist for TENCON excipient innovation?

Generic and private-label supply

The largest opportunity is a reliable, low-cost product with multiple qualified excipient sources. Buyers may value:

• Dual-sourced microcrystalline cellulose and disintegrant suppliers.
• A formulation that avoids supply-constrained colorants.
• Reduced manufacturing cycle time.
• Stable dissolution across multiple acetaminophen grades.
• Domestic or regional contract manufacturing.
• Low minimum-order quantities for specialty pharmacies and private-label distributors.

Patient-acceptability improvements

A film coat can reduce tablet dust, improve swallowability, and create consistent product identification. Taste masking is less valuable than in pediatric or chewable products because TENCON is generally swallowed as a tablet. An orally disintegrating tablet would require a stronger commercial rationale because of the bitter active ingredients and the need to control unintended administration.

Alternative dosage forms

Potential product concepts include:

• Film-coated immediate-release tablets.
• Capsules with powder or multiparticulate fill.
• Unit-dose blister packaging.
• Lower-strength tablets for titration or dose customization.
• A caffeine-free butalbital-acetaminophen product.
• A formulation with improved abuse-deterrence characteristics.

The caffeine-free product would not be a simple generic equivalent to TENCON because it changes the active-ingredient composition. It could require a separate regulatory pathway and clinical or bridging support, depending on the proposed claims and reference product.

Packaging and stability

A high-barrier blister or bottle with desiccant can protect appearance and reduce moisture-related degradation. Packaging innovation is more likely to produce a practical commercial advantage than a broad excipient patent. Unit-dose packaging may also support controlled dispensing, adherence programs, and institutional use.

How does TENCON compare with competing headache products?

Product category	Main advantage	Main limitation	Excipient opportunity
TENCON-type combination	Multi-mechanism symptomatic relief	Dependence, sedation, liver-risk, medication-overuse concerns	Low-cost robust tablet and packaging
Acetaminophen alone	Broad availability and simple labeling	Lower efficacy for some tension headaches	Fast-dissolving or lower-dose formulations
NSAIDs	Anti-inflammatory activity	Gastrointestinal, renal, and cardiovascular risks	Improved tolerability and enteric protection
Triptans	Targeted migraine therapy	Prescription restrictions and narrower indication	Specialized delivery systems
Caffeine-analgesic combinations	Potential efficacy enhancement	Caffeine-related adverse effects and dependence concerns	Dose optimization and caffeine-free alternatives

TENCON competes in a mature market where pricing, availability, pharmacy substitution, and controlled-distribution capability often matter more than formulation novelty.

How strong is the TENCON patent estate?

The patent estate is likely weak at the active-ingredient level because the ingredients are old and widely marketed. Any meaningful protection would need to arise from a later-developed formulation, manufacturing method, packaging system, or narrowly defined method of use.

A commercial diligence review should classify claims into four groups:

1. Core composition claims covering the three active ingredients.
2. Formulation claims covering excipient ratios or processing conditions.
3. Method-of-use claims covering headache treatment or dosing.
4. Manufacturing and packaging claims covering scale-up, stability, or tamper resistance.

The first category is unlikely to provide meaningful exclusivity. The second through fourth categories may create narrower barriers, but their value depends on claim breadth, enforceability, FDA listing, and the ability of generic applicants to design around them.

What licensing and partnering opportunities exist?

Licensing opportunities are more likely to involve manufacturing and distribution than proprietary excipients. Relevant structures include:

• A formulation license to a generic manufacturer.
• A supply agreement for a co-processed direct-compression excipient.
• A private-label agreement with a specialty-pharmacy distributor.
• Contract manufacturing with dual-site production rights.
• A packaging license for unit-dose controlled dispensing.
• A regional commercialization agreement for markets with limited generic supply.

An excipient supplier could create value by offering a validated platform for acetaminophen-containing combination tablets, supported by formulation-development data and a regulatory package. The platform would have broader value if it applies to other analgesic combinations and not only TENCON.

What generic launch scenarios are most plausible?

Scenario 1: Standard ANDA launch

A manufacturer uses conventional excipients, demonstrates bioequivalence, and enters with a low-cost tablet. This is the most likely scenario in a mature market without blocking patent protection.

Scenario 2: Differentiated generic

The applicant uses improved flow, faster disintegration, a new film coat, or a more stable packaging configuration. The product remains an immediate-release tablet but gains supply or operational advantages.

Scenario 3: 505(b)(2) reformulation

A sponsor develops a new dosage form, altered active-ingredient combination, abuse-deterrent formulation, or clinically supported dosing profile. Development costs and regulatory requirements rise sharply, but so may pricing and exclusivity potential.

Scenario 4: Supply-constrained niche product

A regional manufacturer targets pharmacies or institutions that value reliable availability, smaller batch sizes, and controlled-substance compliance. The commercial advantage comes from service and supply continuity rather than patent exclusivity.

Key Takeaways

• TENCON is a mature immediate-release combination of butalbital, acetaminophen, and caffeine.
• The principal commercial opportunity is a reliable, low-cost generic or private-label product.
• Direct compression and dry granulation are the most commercially relevant manufacturing platforms.
• Excipient innovation should focus on flow, content uniformity, dissolution, stability, and supply security.
• Broad patent protection based only on conventional excipient substitution is unlikely to be strong.
• A novel delivery system, abuse-deterrent feature, or clinically meaningful reformulation could support a separate 505(b)(2) strategy.
• Orange Book and Paragraph IV risk must be assessed against the exact TENCON sponsor and current FDA listing.
• Biosimilar risk is irrelevant because TENCON is a small-molecule oral combination.
• Packaging, dual sourcing, and controlled-substance distribution may create more value than a narrow formulation patent.

FAQs

Can a generic manufacturer change TENCON’s colorants?

Yes. A generic may use different inactive ingredients if the change complies with FDA requirements, does not create a safety concern, and does not affect product performance or bioequivalence.

Is TENCON eligible for a biosimilar?

No. TENCON is a small-molecule oral drug product, so competition proceeds through generic drug pathways rather than the biosimilar pathway.

Could TENCON be reformulated as an orally disintegrating tablet?

Yes, but the product would face taste, dose uniformity, moisture, and handling challenges. A materially different dosage form may require a regulatory pathway other than a conventional ANDA.

Would a caffeine-free TENCON product be therapeutically equivalent?

No. Removing caffeine changes the active-ingredient composition. The resulting product would not be therapeutically equivalent to the three-ingredient TENCON formulation without a separate regulatory basis.

Do excipient patents provide strong protection for TENCON?

Usually not when they cover routine substitutions of common fillers, binders, lubricants, or disintegrants. Stronger protection requires a defined composition tied to unexpected performance, stability, manufacturing, or patient-use results.

References

1. U.S. Food and Drug Administration. (n.d.). Butalbital, acetaminophen, and caffeine prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. National Library of Medicine. (n.d.). TENCON and butalbital, acetaminophen, caffeine tablet labeling. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2019). Inactive ingredient database guidance and database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Food and Drug Administration. (2017). ANDA submissions: Content, format, and application review. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

6. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/frequently-asked-questions-505b2-regulatory-pathway